<DOC>
	<DOCNO>NCT02001103</DOCNO>
	<brief_summary>The specific aim project test memantine add-on therapy helpful patient first episode schizophrenia present without cognitive impairment negative symptom , examine efficacy safety memantine adjuvant agent ongoing maintenance therapy atypical antipsychotic . Our objective include : 1 . Test memantine add-on 2 different dosage compare placebo-controlled group clinically stable first episode schizophrenic patient second-generation antipsychotic maintenance therapy . The result give u information regard effective dosage profile adverse drug reaction use population . 2 . Examine whether effect memantine add-on affected significant baseline clinical variable predispose cognitive deficit . That say , memantine demonstrate adjunctive effect cognitively impaired effect independent baseline cognitive functioning severity baseline psychopathology . 3 . Examine change negative symptom secondary outcome see cognitive enhance effect concurrent improvement negative symptom independent change negative symptom . 4 . Treat change positive symptom clinical outcome , readmission , employed/going back school , psycho-social functioning score tertiary outcome examine effectiveness memantine add-on .</brief_summary>
	<brief_title>Memantine add-on Cognitive Negative Symptoms Schizophrenia</brief_title>
	<detailed_description>Study design : This 12-week double-blind randomize placebo-controlled trial memantine add-on concurrent antipsychotic therapy clinically stable patient first episode schizophrenia . Study procedure : Patients recruit outpatient clinic study hospital . We hold information campaign encourage referral clinical trial procedure set . Patients assess eligibility base criterion detail . Written inform consent obtain eligible subject subject ' parent young age 18 year . Baseline clinical neuropsychological assessment do first . Patients receive single dose memantine 5 mg test allergic reaction never use . And randomize 3 group : first group receive target dose memantine 10 mg/day , second group receive target dose memantine 20 mg/day , third placebo control group . Both participant clinician blind agent dosage take . The dose titrating schedule medication group 5 mg/day first week increment 5 mg per week reach designate target dose . So the10 mg add-on group reach target dose begin second week 20 mg/day add-on group reach target dose begin fourth week . Participants schedule return visit week 1 , 2 , 4 , 8 , 12 dispense medication clinical assessment . By end 12-week trial , receive clinical neuropsychological assessment . To use least resource make use information , well take account attrition , plan recruit 40 patient group total 120 participant .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Memantine</mesh_term>
	<criteria>Both male female outpatient Age 1845 year old time screen A diagnosis schizophrenia base Structured Clinical Interview DSMIV Currently receive treatment mainly atypical antipsychotic ( risperidone , olanzapine , amisulpride , aripiprazole , quetiapine , ziprasidone , paliperidone ) , include longacting injectable antipsychotic A first generation antipsychotic agent lowdose , need use purpose No revise use benzodiazepine , antidepressant , anticholinergic , concomitant medication past 3 month A score 5 7 positive symptom item PANSS rating screen Scores 4 least 3 7 positive symptom item PANSS rating screen Currently clozapine treatment A change current antipsychotic medication recent 3 month Mental retardation know IQ 70 prior diagnosis schizophrenia A history pervasive mental disorder bipolar disorder A medical condition significant cognitive sequela A history substance dependence A history hypersensitivity memantine drug class , amantadine Pregnancy , plan get pregnant study period , lactate woman Abnormal liver function ( AST , ALT high double upper limit normal range ) abnormal renal function ( blood creatinine &gt; 1.3 mg/dL ) A history epilepsy A history myocardial infarction , congestive heart failure , uncontrolled hypertension , stroke , severe heart block .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>adjuvant therapy</keyword>
	<keyword>cognitive deficit</keyword>
	<keyword>first episode schizophrenia</keyword>
	<keyword>glutamate hypothesis</keyword>
	<keyword>memantine</keyword>
	<keyword>negative symptom</keyword>
</DOC>